1. **ALLERGIES/REACTIONS:**

2. **DIAGNOSIS:** Anemia due to chronic Kidney Disease  □ Stage 3  □ Stage 4  □ Stage 5

   **DIAGNOSIS/ICD-CDM CODE(S):**

   GFR ___________________ on date: ____________ (Must be less than 60 ml/minute to initiate this pre-printed order).

3. **EXCLUSION CRITERIA:** Uncontrollable hypertension, active bleeding or allergic to darbepoetin Alfa

4. Height: ________ cm  Weight ___________ kg

5. In clinical trials, Erythropoiesis Stimulating Agents (ESA) shortened overall survival and/or increased the risk of tumor progression or recurrence in cancer patients. It is crucial that shared providers discuss ESA treatment before administration when caring for Chronic Kidney Disease patients who have cancer as it may trigger the ESA APPRISE (Assisting Providers and Cancer Patients on the Risks Information for the Safe use of ESAs) program and/or other required actions for care.

6. **LABS:**

   **BASELINE LABS: DIAGNOSIS/ICD-CDM CODE(S):**

   Baseline Lab results MUST be available prior to appointment for darbepoetin alfa therapy:

   Hgb/Hct, Fe/TIBC, Ferritin, B-12, Folate. **Note the following:**

   - Hgb must be less than 10g/dl and drawn within seven days of initiation of darbepoetin alfa. Iron, folate and B12 deficiencies must be corrected as appropriate prior to initiating darbepoetin alfa.
   - If IV iron is given, draw a Hgb/Hct two weeks after the last dose of IV iron before initiation of darbepoetin alfa.
   - If Hgb is above 10 g/dl check Hgb every two weeks times two. If still above 10 g/dl notify physician and discharge from service.
   - □ Other labs with DIAGNOSIS/ICD-CDM CODE(S): ________________

   **MONITORING LABS: DIAGNOSIS/ICD-CDM CODE(S):**

   - Draw Fe/TIBC, ferritin levels every three months and notify provider if TSAT is less than or equal to 30% and ferritin is less than 500 ng/ml for possible IV iron orders.
   - Hgb/Hct drawn at least once a month or every two weeks based on darbepoetin alfa dosing Table.
   - □ Other labs with DIAGNOSIS/ICD-CDM CODE(S): ________________

Provider initials_________________
7. MEDICATIONS (continued)

All doses of darbepoetin Alfa will be given subcutaneously unless otherwise specified:

A. Darbepoetin alfa dosing per table for initial dosing

<table>
<thead>
<tr>
<th>Weeks</th>
<th>Initial dose</th>
<th>Hgb Below 10 g/dl</th>
<th>Hgb 10 -10.5 g/dl</th>
<th>Hgb 10.6-11 g/dl</th>
<th>Hgb 11.1 g/dl and above</th>
</tr>
</thead>
<tbody>
<tr>
<td>Week 1</td>
<td>0.45 mcg/kg give subcutaneously return in 2 weeks</td>
<td>Hgb must be below 10 g/dl to start and Hgb/Hct results within 7 days before starting.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 3</td>
<td>Give same dose and return in 2 weeks with Hgb/Hct labs.</td>
<td>No dose, return in 2 weeks with Hgb/Hct labs.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Week 5</td>
<td>Increase dose by 25% give and return in 2 weeks with Hgb/Hct labs.</td>
<td>Give same dose and return in 2 weeks with Hgb/Hct labs.</td>
<td>Reduce dose by 25% give and return in 2 weeks with Hgb/Hct labs.</td>
<td>No dose, return in 2 weeks with Hgb/Hct labs.</td>
<td></td>
</tr>
<tr>
<td>Week 7</td>
<td>• If dose has not been increased within 28 days, increase dose by 25% give and return in 2 weeks with Hgb/Hct labs.</td>
<td>• If patient did not receive same dose for weeks 3 and 5- give same dose and return in two weeks with Hgb/Hct labs.</td>
<td>• If patient’s Hgb has been between 10-11g/dl for consecutive weeks 3 and 5 and received the same dose, increase dose by 25% give and return in one month with Hgb/Hct labs.</td>
<td>• If Hgb is still above 11 g/dl after holding 2 consecutive doses, hold dose and notify provider for possible discharge of service.</td>
<td>• Hold dose if it does not meet the above condition, and return in 2 weeks with Hgb/Hct labs.</td>
</tr>
</tbody>
</table>

B. Darbepoetin alfa dosing per table for Maintenance dosing:

<table>
<thead>
<tr>
<th>Week 9 and after</th>
<th>Hgb Below 10 g/dl</th>
<th>Hgb 10 -10.5 g/dl</th>
<th>Hgb 10.6-11 g/dl</th>
<th>Hgb 11.1 g/dl and above</th>
</tr>
</thead>
<tbody>
<tr>
<td>On 2-week dosing</td>
<td>• If dose has not been increased within 28 days, increase dose by 25% give and return in 2 weeks with Hgb/Hct labs.</td>
<td>• If patient did not receive same dose for the last 2 consecutive weeks (i.e. 4 weeks-total) give same dose and return in two weeks with Hgb/Hct labs.</td>
<td>• If patient’s Hgb has been between 10-11g/dl for 2-consecutive weeks (i.e. 4 weeks-total) and received the same dose, increase dose by 25% give and return in 4 weeks with Hgb/Hct labs.</td>
<td>• If Hgb is still above 11 g/dl after holding 2 consecutive doses, notify provider for possible discharge of service and hold dose.</td>
</tr>
</tbody>
</table>

Provider initials___________________
Continued: Darbepoetin alfa dosing per table for Maintenance dosing:

<table>
<thead>
<tr>
<th>Week 9 and after</th>
<th>Hgb Below 10 g/dl</th>
<th>Hgb 10 -10.5 g/dl</th>
<th>Hgb 10.6-11 g/dl</th>
<th>Hgb 11.1 g/dl and above</th>
</tr>
</thead>
<tbody>
<tr>
<td>On 4-week dosing</td>
<td>Increase dose by 25% and return in 4 weeks with Hgb/Hct labs.</td>
<td>Give same dose and return in 4 weeks with Hgb/Hct labs.</td>
<td>No dose, return in 2 weeks with Hct/Hgb labs. If still above continue to hold and return in 2 weeks with Hgb/Hct labs. Once Hgb is below 11.1 g/dl reduce dose by 25% and return in 4 weeks with Hgb/Hct labs.</td>
<td></td>
</tr>
</tbody>
</table>

ADDITIONAL DOSING GUIDELINES FOR DARBEPOETIN ALFA:
- If the patient’s Hgb rises by 1g/dl in any 2 week period notify provider
- Dosing increase can only occur once in 28 days. Decreasing dose can occur more often, but avoid reducing frequently (note trends).
- For patients who have not responded to the target Hgb 10 g/dl over a 12-week period notify provider
- If patient missed a dose, (i.e. did not make their appt) notify provider.
- Dosing for darbepoetin alfa-round DOWN to the nearest 5 mcg.

C. Dose per provider (if not using the dosing table). Maxmium dosing is 200 mcg/week or 800 mcg/month.

Darbepoetin Alfa___________mcg subcutaneously every___________weeks. Call physician for dose adjustments to keep Hgb within 10-11 g/dl.

D. Patient is currently receiving darbepoetin alfa___________mcg subcutaneously every_______weeks. Proceed using the dose adjustment table listed in this order.

8. TREATMENT:
A. Initiate Drug Related Hypersensitivity Physician Orders #774 as appropriate.

Notify physician if:
- Systolic blood pressure is greater than 180 mmHg
- Diastolic blood pressure greater than 110 mmHg
- Weight gain greater than 3 kg 1-2 weeks from last visit.
- If patient has recently received pRBC transfusions notify provider to hold darbepoetin Alfa
- Refer to darbepoetin Alfa table for additional situations when to notify provider.

9. EDUCATION:
- Provide patients with the darbepoetin alfa (Aranesp) medication guide at the initiation of therapy.

NOTE: These orders should be reviewed by the attending physician, appropriately modified for the individual patient, dated, timed and signed below.

DATE     TIME     PROVIDER’S SIGNATURE

Another brand of drug, identical in form and content, may be dispensed unless checked. ☐